1. In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:
a. Abemaciclib monotherapy
b. Aromatase inhibitor monotherapy (e.g. anastrazole, exemestane, letrozole)
c. Tamoxifen monotherapy
d. Abemaciclib + Tamoxifen
2. In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:
a. Abemaciclib + Aromatase inhibitor (e.g. anastrazole, exemestane, letrozole)
b. Taxane and/or Anthracycline (monotherapy or in combination)
c. Any other active systemic anti cancer therapy
3. How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies:
a. Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
b. Atezolizumab +Nab-paclitaxel/Paclitaxel
c. Pembrolizumab
d. Sacituzumab Govitecan
e. Parp Inhibitors (Olaparib/Talazoparib)
f. Eribulin as a single agent or in combination
g. Capecitabine as a single agent
h. Platinum (e.g. carboplatin or cisplatin) as a single agent
i. Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
j. Taxane and/or Anthracycline in combination
k. Any other active systemic anti-cancer therapy
